Lanreotide

Lanreotide is a prescription medication used for the treatment of acromegaly.

• Lanreotide is available under the following different brand names: Somatuline Depot

Common side effects of Lanreotide include:

• headache,
• pounding in the neck or ears,
• dizziness,
• nausea,
• vomiting,
• diarrhea,
• stomach pain,
• muscle or joint pain,
• headache,
• dizziness, and
• pain, itching, or a hard lump where the medicine was injected

Serious side effects of Lanreotide include:

• hives,
• difficulty breathing,
• swelling of the face, lips, tongue, or throat,
• chest pain,
• slow heartbeats,
• shortness of breath,
• lightheadedness,
• confusion,
• memory problems,
• weakness,
• tiredness,
• headache,
• hunger,
• sweating,
• irritability,
• dizziness,
• fast heart rate,
• anxiousness,
• shakiness,
• increased thirst,
• increased urination,
• dry mouth,
• fruity breath odor,
• depressed mood,
• dry skin,
• thinning hair,
• decreased sweating,
• weight gain,
• puffiness in the face,
• increased sensitivity to cold temperatures,
• sudden severe pain in your upper stomach spreading to the back or shoulder,
• nausea,
• fever,
• chills, and
• yellowing of the skin or eyes (jaundice)

Rare side effects of Lanreotide include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Injection solution

• 60 mg/0.2 mL
• 90 mg/0.3 mL
• 120 mg/0.5 mL

Acromegaly

Adult dosage

• 90mg SC every 4 weeks  for 3 months; THEN adjust based on GH and/or IGF-1 levels
• Dose adjustments after 3 months
• GH more than 1 to less than 2.5 ng/mL, IGF-1 normal and clinical symptoms controlled: Maintain dose at 90 mg every 4 weeks
• GH more than 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: Increase dose to 120 mg every 4 weeks
• GH less than 1 ng/mL, IGF-1 normal and clinical symptoms controlled: Reduce dose to 60 mg every 4 weeks
• Patients controlled on 60-90 mg every 4 weeks may be considered for an extended dosing interval of 120 mg every 6-8 weeks.

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Lanreotide has severe interactions with no other drugs.
• Lanreotide has serious interactions with the following  drugs:
  • ponesimod
  • vilazodone
• Lanreotide has moderate interactions with at least 23 other drugs.
• Lanreotide has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• Hypersensitivity to lanreotide

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Lanreotide?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Lanreotide?”

Cautions

• Risk of reducing gallbladder motility, which could lead to gallstone formation; monitor periodically
• Inhibition of insulin and glucagon secretion; may affect glucose regulation, which can lead to hyper-hypoglycemia; glucose monitoring is recommended; adjust antidiabetic treatment accordingly
• Decreases in thyroid function reported; thyroid function tests are recommended where clinically indicated
• Bradycardia, hypertension, and sinus bradycardia reported; use with caution in at-risk patients; initiate appropriate medical management in patients who develop symptomatic bradycardia
• Pharmacological gastrointestinal effects of lanreotide may reduce the intestinal absorption of concomitant drugs; lanreotide may decrease the relative bioavailability of cyclosporine; concomitant administration of lanreotide and cyclosporine may necessitate the adjustment of cyclosporine dose to maintain therapeutic levels
• Cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, and pancreatitis, and requiring cholecystectomy reported; if complications of cholelithiasis are suspected, discontinue therapy and treat appropriately
• Use caution in renal/hepatic impairment, diabetes

Pregnancy and Lactation

• Limited available data based on postmarketing case reports, use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes
• A reproductive study in pregnant rats given 30 mg/kg of lanreotide by subcutaneous injection every 2 weeks (5 times the human dose, based on body surface area comparisons) resulted in decreased embryo/fetal survival
• Lactation
  • There is no information available on the presence of lanreotide in human milk, the effects of the drug on the breastfed infant, or on milk production; studies show that lanreotide acetate administered subcutaneously passes into the milk of lactating rats; due to specifies-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk
  • Because of potential for serious adverse reactions in breastfed infants, including effects on glucose metabolism and bradycardia, advise women not to breastfeed during treatment and for 6 months (6 half-lives) following the last dose